BioLineRx (NASDAQ:BLRX) Cut to Sell at StockNews.com

StockNews.com cut shares of BioLineRx (NASDAQ:BLRX) from a hold rating to a sell rating in a report issued on Tuesday.

Separately, HC Wainwright cut their price target on shares of BioLineRx from $840.00 to $360.00 and set a “buy” rating for the company in a report on Monday, November 25th.

BioLineRx Stock Performance

Shares of BioLineRx stock opened at $3.42 on Tuesday. The company has a 50 day moving average of $3.74 and a 200-day moving average of $12.03. BioLineRx has a 1-year low of $2.88 and a 1-year high of $56.00. The company has a current ratio of 1.52, a quick ratio of 1.37 and a debt-to-equity ratio of 2.11. The company has a market cap of $11.39 million, a PE ratio of -0.39 and a beta of 1.39.

Hedge Funds Weigh In On BioLineRx

A hedge fund recently raised its stake in BioLineRx stock. Atria Investments Inc increased its stake in shares of BioLineRx Ltd. (NASDAQ:BLRX) by 27.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 133,974 shares of the biotechnology company’s stock after purchasing an additional 29,193 shares during the quarter. Atria Investments Inc owned approximately 0.17% of BioLineRx worth $72,000 at the end of the most recent reporting period. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.